Undesirable effects are listed by MedDRA System Organ Classes.
Assessment of undesirable effects is based on the following frequency groupings:
Very common: ≥ 1/10
Common: ≥ 1/100 to <1/10
Uncommon: ≥ 1/1,000 to <1/100
Rare: ≥ 1/10,000 to <1/1,000
Very rare: <1/10,000
Not known: cannot be estimated from the available data
Gastrointestinal disorders | Not known: Gastrointestinal disturbance (including nausea) Taste disturbance (including metallic taste) |
Experience with potassium iodate is limited.The following side effects can occur with potassium iodide.
Hypersensitivity reactions such as skin rashes, swollen salivary glands, headache and bronchospasm can be mild or severe and may be dose dependent.
Hyperthyroidism, iodine induced autoimmunity (Grave's and Hashimoto type), toxic nodular goitre and iodine-induced hypothyroidism have been reported as side effects of iodine therapy.
An overactive thyroid gland, thyroiditis, and an enlarged thyroid gland with or without development or myxoedema have also been reported.
Continued administration may lead to mental depression, nervousness, sexual impotence and insomnia.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme
Tel: Freephone 0808 100 3352
Website: www.mhra.gov.uk/yellowcard